KR102646996B1 - Composition Comprising Harpagoside for Wound Healing - Google Patents
Composition Comprising Harpagoside for Wound Healing Download PDFInfo
- Publication number
- KR102646996B1 KR102646996B1 KR1020210034530A KR20210034530A KR102646996B1 KR 102646996 B1 KR102646996 B1 KR 102646996B1 KR 1020210034530 A KR1020210034530 A KR 1020210034530A KR 20210034530 A KR20210034530 A KR 20210034530A KR 102646996 B1 KR102646996 B1 KR 102646996B1
- Authority
- KR
- South Korea
- Prior art keywords
- wound
- harpagoside
- composition
- wound healing
- wounds
- Prior art date
Links
- 230000029663 wound healing Effects 0.000 title claims abstract description 24
- KVRQGMOSZKPBNS-FMHLWDFHSA-N Harpagoside Chemical compound O([C@@H]1OC=C[C@@]2(O)[C@H](O)C[C@]([C@@H]12)(C)OC(=O)\C=C\C=1C=CC=CC=1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KVRQGMOSZKPBNS-FMHLWDFHSA-N 0.000 title claims abstract description 21
- KVRQGMOSZKPBNS-BYYMOQGZSA-N Harpagoside Natural products C[C@@]1(C[C@@H](O)[C@@]2(O)C=CO[C@@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@H]12)OC(=O)C=Cc4ccccc4 KVRQGMOSZKPBNS-BYYMOQGZSA-N 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 206010052428 Wound Diseases 0.000 claims abstract description 53
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 52
- 239000003814 drug Substances 0.000 claims abstract description 21
- 230000001737 promoting effect Effects 0.000 claims abstract description 8
- 150000003431 steroids Chemical class 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 19
- 230000003111 delayed effect Effects 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000005556 hormone Substances 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 3
- 230000035876 healing Effects 0.000 claims description 3
- -1 patch Substances 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 11
- 210000003491 skin Anatomy 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000003470 adrenal cortex hormone Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000023329 Gun shot wound Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- ATDBDSBKYKMRGZ-ZDUSSCGKSA-N Cimifugin Chemical compound O1C(CO)=CC(=O)C2=C1C=C1O[C@H](C(C)(C)O)CC1=C2OC ATDBDSBKYKMRGZ-ZDUSSCGKSA-N 0.000 description 1
- ATDBDSBKYKMRGZ-UHFFFAOYSA-N Cimifugin Natural products O1C(CO)=CC(=O)C2=C1C=C1OC(C(C)(C)O)CC1=C2OC ATDBDSBKYKMRGZ-UHFFFAOYSA-N 0.000 description 1
- UNPLRYRWJLTVAE-UHFFFAOYSA-N Cloperastine hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)OCCN1CCCCC1 UNPLRYRWJLTVAE-UHFFFAOYSA-N 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 244000082490 Proboscidea louisianica Species 0.000 description 1
- 235000015926 Proboscidea louisianica ssp. fragrans Nutrition 0.000 description 1
- 235000015925 Proboscidea louisianica subsp. louisianica Nutrition 0.000 description 1
- 235000019096 Proboscidea parviflora Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010041899 Stab wound Diseases 0.000 description 1
- OFECPTGTEKSUPH-UHFFFAOYSA-N Visamminol Natural products CC1=CC(=O)c2cc3CC(Oc3cc2O1)C(C)(C)O OFECPTGTEKSUPH-UHFFFAOYSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 하파고사이드(Harpagoside)를 포함하는 상처 치료 또는 상처 치료 촉진용 조성물에 관한 것이다. 본 발명의 하파고사이드(Harpagoside)를 포함하는 조성물은 상처 치료 효능이 뛰어나므로, 상처 치료를 위한 피부 외용제를 비롯한 의약품 등에 적용되어 사용될 수 있을 것이다. The present invention relates to a composition for treating wounds or promoting wound healing, including Harpagoside. Since the composition containing Harpagoside of the present invention has excellent wound healing efficacy, it can be used in pharmaceuticals, including external skin preparations for wound treatment.
Description
본 발명은 하파고사이드를 포함하는 상처 치료용 조성물에 관한 것이다.The present invention relates to a composition for treating wounds containing harpagoside.
우리 몸에서 피부는 여러 가지 기능을 담당하고 있으며, 그 중에서도 가장 중요한 기능은 외부로부터 우리의 몸을 보호하는 장벽 역할이라 할 수 있다. 피부의 정상적인 구조가 파괴된 상태를 창상 혹은 상처라고 한다. 이와 같이 피부가 상처를 입게 되면 상처 부위가 노출되어 외부 균의 침입을 받을 수 있다. 따라서, 신속한 상처치료가 되어야 추가 감염(infection)을 막을 수 있고 또한, 그로 인한 과도한 염증반응(inflammation)을 막을 수 있다. 과도한 염증반응은 상처치유 기간을 연장시킬 뿐 아니라 흉터의 원인이 되기도 한다.The skin performs various functions in our body, and the most important function among them is that it acts as a barrier that protects our body from the outside. A state in which the normal structure of the skin is destroyed is called a wound or wound. When the skin is injured in this way, the wound area is exposed and can be invaded by external bacteria. Therefore, prompt wound treatment is required to prevent additional infection and excessive inflammation. Excessive inflammatory response not only prolongs the wound healing period but also causes scarring.
상처치유(wound healing)란 임상적으로 피부가 완전하게 봉합되는 것을 의미하며, 만성상처(chronic wound)가 아닌 일반적인 상처는 대략 3-14일 안에 완전히 치유된다. 상처치유는 각질세포(keratinocyte), 섬유아세포(fibroblast), 혈관내피세포(endothelial cell), 대식세포(macrophage), 혈소판(platelet) 등 여러 종류의 세포가 상호작용하면서 조절하는 복잡한 과정으로 이루어진다.Wound healing clinically means complete suturing of the skin, and normal wounds, not chronic wounds, are completely healed in approximately 3-14 days. Wound healing is a complex process in which various types of cells, including keratinocytes, fibroblasts, endothelial cells, macrophages, and platelets, interact and regulate each other.
스테로이드제제는 면역억제를 통하여 피부염증을 조절해주지만, 각질형성세포의 증식을 억제하거나, 세포증식을 억제함으로써 상처치유를 지연시킨다. 이와 같이, 스테로이드제 등으로 인하여 상처 치료가 지연되면 2차 감염 등 다른 위험이 증가하게 되므로, 상처치료제의 개발은 여전히 필요한 실정이다. Steroids control skin inflammation through immunosuppression, but they delay wound healing by inhibiting the proliferation of keratinocytes or inhibiting cell proliferation. Likewise, if wound healing is delayed due to steroids, etc., other risks such as secondary infection increase, so the development of wound treatment agents is still necessary.
일 양상은 하파고사이드(Harpagoside)를 포함하는 상처 치료용 약학적 조성물을 제공하는 것이다. One aspect is to provide a pharmaceutical composition for treating wounds comprising Harpagoside.
다른 양상은 하파고사이드(Harpagoside)를 포함하는 상처 치료 촉진용 의약외품 조성물을 제공하는 것이다. Another aspect is to provide a quasi-drug composition for promoting wound healing containing Harpagoside.
일 양상은 하파고사이드(Harpagoside)를 포함하는 상처 치료용 약학적 조성물을 제공하는 것이다. One aspect is to provide a pharmaceutical composition for treating wounds comprising Harpagoside.
상기 하파고사이드는 악마의 발톱 또는 천수근이라고 일컫는 식물의 주성분일 수 있으며, 하기 화학식과 같은 물질일 수 있다. The harpagoside may be a main component of a plant called devil's claw or apricot root, and may be a substance shown in the chemical formula below.
상기 상처는 외부의 압력 등에 의한 피부 상피조직의 온전함이 파괴되는 것을 나타내는 의미로서, 창상(創傷)이라고도 할 수 있다. 상기 상처의 종류로는 찰과상, 타박상, 열상, 칼날에 의한 절창, 자창(刺創), 할창(割創), 총창(銃創), 폭창, 교창(咬創) 등이 있으나, 이에 제한되지 않는다.The wound refers to the destruction of the integrity of the skin epithelial tissue due to external pressure, etc., and can also be called a wound. Types of the above wounds include, but are not limited to, abrasions, bruises, lacerations, cuts caused by blades, stab wounds, puncture wounds, bullet wounds, gunshot wounds, and gunshot wounds.
일 구체예에 따르면, 상기 상처는 스테로이드제로 인하여 상처치유가 지연된 상처일 수 있다. 상기 스테로이드제제로 인하여 지연된 상처는 스테로이드제제가 각질형성세포의 증식을 억제하거나, 세포증식을 억제함으로써 지연되는 것일 수 있다. 상기 상처치유가 지연된 상처는 스테로이드제를 사용하여 상처가 지연된 것일 수 있고, 스테로이드제를 지속하여 사용하고 있어 상처 치유의 지연이 진행되고 있는 상처일 수 있다. According to one embodiment, the wound may be one in which wound healing has been delayed due to steroid medication. Wounds delayed by the steroid preparation may be delayed because the steroid preparation inhibits the proliferation of keratinocytes or inhibits cell proliferation. The wound with delayed healing may be a wound that has been delayed due to the use of steroids, or may be a wound in which wound healing is delayed due to continuous use of steroids.
일 구체예에 따르면, 상기 스테로이드제는 부신피질호르몬제, 남성호르몬제, 여성호르몬제일 수 있으나, 예를 들면 부신피질호르몬제 일 수 있다. 상기 부신피질호르몬제는 항염증 효과 및 면역억제효과를 가지는 약물로, 발적, 부종, 열감, 압통 등의 증상을 현저히 감소시킬 수 있는 제제일 수 있으며, 신체의 면역기능이 저하되어 세균 감염이 잘 유발되거나 악화되는 부작용이 나타날 수 있다. 상기 부신피질호르몬제는 덱타메타손, 히드로코르티손, 프레드니솔론, 베타메타손일 수 있으나, 이에 제한되지 않는다.According to one embodiment, the steroid agent may be an adrenocorticosteroid agent, a male hormone agent, or a female hormone agent. For example, it may be an adrenocorticosteroid agent. The corticosteroid agent is a drug that has an anti-inflammatory effect and an immunosuppressive effect. It can be a drug that can significantly reduce symptoms such as redness, swelling, heat, and tenderness, and the immune function of the body is reduced, making bacterial infections more likely. Side effects may occur or worsen. The corticosteroid agent may be dextamethasone, hydrocortisone, prednisolone, or betamethasone, but is not limited thereto.
일 실시예에 따르면, 스테로이드제를 처리한 상처의 경우, 상처치유가 되지 않았으며, 스테로이드제를 처리한 상처에 시미푸긴을 사용한 경우 스테로이드제만 처리한 상처 대비 현저히 상처치유가 진행되는 것을 확인하였다. According to one example, in the case of wounds treated with steroids, wound healing did not occur, and when cimifugin was used on wounds treated with steroids, it was confirmed that wound healing progressed significantly compared to wounds treated only with steroids. .
상기 '상처 치료'는 상처치유와 동등한 의미일 수 있으며, 파괴된 피부의 상피조직이 온전해지는 모든 과정을 포함하는 의미이다.The term 'wound treatment' may have the same meaning as wound healing, and includes all processes by which the damaged epithelial tissue of the skin becomes intact.
한편, 본 발명의 약학적 조성물은 각각 통상의 방법에 따라 다양한 형태로 제형화하여 사용될 수 있다. 예컨대, 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽 등의 경구형 제형으로 제형화할 수 있고, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 다만, 본 발명의 조성물은 상처 치료라는 목적상 피부 외용제의 형태로 제공되는 것일 수 있다. 예를 들면, 액제, 연고제, 크림제, 로션제, 스프레이제, 패취제, 겔제 또는 에어로졸제 등의 피부 외용제의 형태로 사용될 수 있다.Meanwhile, the pharmaceutical composition of the present invention can be formulated and used in various forms according to conventional methods. For example, it can be formulated into oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, etc., and can be formulated and used in the form of external preparations, suppositories, and sterile injection solutions. However, the composition of the present invention may be provided in the form of an external skin preparation for the purpose of treating wounds. For example, it can be used in the form of external skin preparations such as liquid, ointment, cream, lotion, spray, patch, gel, or aerosol.
또한, 각각의 제형에 따라 약학적으로 허용 가능한 담체, 예컨대 완충제, 보존제, 무통화제, 가용화제, 등장제, 안정화제, 기제, 부형제, 윤활제 등 당업계에 공지된 담체를 추가로 포함하여 제조할 수 있다. 예컨대, 상처 부위에 국부적으로 사용되는 피부 외용제인 경우에는 통상적인 첨가제, 예를 들어 보존제, 의약 침투를 보조하는 용매, 연고 및 크림의 경우 연화제 등을 포함할 수 있으며, 에탄올 또는 올레일 알코올과 같은 통상적 담체를 함유할 수 있다. In addition, each formulation may be prepared by additionally including pharmaceutically acceptable carriers such as buffers, preservatives, analgesics, solubilizers, isotonic agents, stabilizers, bases, excipients, lubricants, etc. known in the art. You can. For example, in the case of external skin preparations used topically on wounds, they may contain conventional additives such as preservatives, solvents that assist drug penetration, and emollients in the case of ointments and creams, such as ethanol or oleyl alcohol. May contain conventional carriers.
또한, 본 발명의 약학적 조성물에는, 상처 치료에 일반적으로 사용되는 화합물, 예컨대 항생제, 피부 치료용 조제, 마취제 및 진통제 등을 추가로 포함할 수 있다. 이는, 각각의 제형에 따라 약간씩 변화될 수 있으며, 바람직하게는 피부 외용제의 형태로 제공되는 경우에 포함될 수 있으나, 이에 제한되는 것은 아니다. 일반적으로, 상처부위의 감염을 방지하거나 감염으로 인한 상처의 악화를 방지하기 위하여 상처부위에 항생제, 항균제 등의 약제를 공급할 수 있고, 또한 통증의 완화를 위하여 국소 마취제 및 진통제 등을 공급할 수 있다. 다양한 기능성 약제들을 함유시켜 공급함으로써, 사용상의 편리성을 도모하고, 효율적인 상처치유에 도움이 되는 환경을 조성함으로써 상처치유 효과를 더욱 향상시킬 수 있다.In addition, the pharmaceutical composition of the present invention may further include compounds commonly used in wound treatment, such as antibiotics, skin treatment preparations, anesthetics, and analgesics. This may vary slightly depending on each formulation, and may preferably be included when provided in the form of an external skin preparation, but is not limited thereto. In general, medications such as antibiotics and antibacterial agents can be supplied to the wound site to prevent infection or worsening of the wound due to infection, and local anesthetics and painkillers can also be supplied to relieve pain. By containing and supplying various functional drugs, the wound healing effect can be further improved by promoting convenience of use and creating an environment conducive to efficient wound healing.
한편, 본 발명의 약학적 조성물은 약학적으로 유효한 양으로 투여한다. 본 발명의 용어 "약학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분하며 부작용을 일으키지 않을 정도의 양을 의미하며, 유효용량 수준은 환자의 건강상태, 상처의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 방법, 투여 시간, 투여 경로 및 배출 비율, 치료기간, 배합 또는 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다.Meanwhile, the pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. The term "pharmaceutically effective amount" of the present invention refers to an amount that is sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment and does not cause side effects, and the effective dose level refers to the patient's health condition, Factors including the type of wound, severity, activity of the drug, sensitivity to the drug, method of administration, time of administration, route of administration and excretion rate, duration of treatment, drugs combined or used simultaneously, and other factors well known in the medical field. You can.
다른 양상은 하파고사이드(Harpagoside)를 포함하는 상처 치료 촉진용 의약외품 조성물을 제공하는 것이다. Another aspect is to provide a quasi-drug composition for promoting wound healing containing Harpagoside.
상기 하파고사이드, 상처, 및 하파고사이드의 상처 치료 효능에 대해서는 상기 설명한 바와 같으며, 본 발명의 조성물은 상처의 치료 또는 개선 목적으로 의약외품에 첨가될 수 있다. The harpagoside, wounds, and the wound healing efficacy of harpagoside are as described above, and the composition of the present invention can be added to quasi-drugs for the purpose of treating or improving wounds.
상기 '상처 치료 촉진'은 상처치유 촉진과 동일한 의미일수 있으며, 파괴된 피부의 상피조직이 온전해지는 모든 과정이 촉진되는 것을 포함하는 의미이다.The term 'promoting wound healing' may have the same meaning as promoting wound healing, and includes promoting all processes to restore intact epithelial tissue of destroyed skin.
상기 '의약외품'은 사람이나 동물의 질병을 치료, 경감, 처치 또는 예방할 목적으로 사용되는 섬유, 고무제품 또는 이와 유사한 것, 인체에 대한 작용이 약하거나 인체에 직접 작용하지 아니하며, 기구 또는 기계가 아닌 것과 이와 유사한 것, 감염병 예방을 위하여 살균, 살충 및 이와 유사한 용도로 사용되는 제제 중 하나에 해당하는 물품으로서, 사람이나 동물의 질병을 진단, 치료, 경감, 처치 또는 예방할 목적으로 사용하는 물품 중 기구, 기계 또는 장치가 아닌 것 및 사람이나 동물의 구조와 기능에 약리학적 영향을 줄 목적으로 사용하는 물품 중 기구, 기계 또는 장치가 아닌 것을 제외한 물품을 의미한다.The above ‘quasi-drugs’ are fibers, rubber products or similar products used for the purpose of treating, alleviating, treating or preventing diseases in humans or animals, have a weak effect on the human body or do not act directly on the human body, and are not instruments or machines. It is one of the products used for sterilization, insecticide and similar purposes to prevent infectious diseases, and is a device used for the purpose of diagnosing, treating, mitigating, treating or preventing diseases in humans or animals. , refers to articles that are not machines or devices, and articles used for the purpose of having a pharmacological effect on the structure and function of humans or animals, excluding those that are not instruments, machines, or devices.
본 발명의 조성물을 의약외품 첨가물로 사용할 경우, 상기 조성물을 그대로 첨가하거나 다른 의약외품 또는 의약외품 성분과 함께 사용할 수 있고, 통상적인 방법에 따라 적절하게 사용할 수 있다. 유효성분의 혼합량은 사용 목적에 따라 적합하게 결정될 수 있다.When using the composition of the present invention as a quasi-drug additive, the composition can be added as is or used together with other quasi-drugs or quasi-drug components, and can be used appropriately according to conventional methods. The mixing amount of the active ingredient can be appropriately determined depending on the purpose of use.
본 발명의 의약외품 조성물은 이에 제한되지는 않으나, 바람직하게는 소독청결제, 샤워폼, 구강 청정제(가그린), 물티슈, 세제비누, 핸드워시, 가습기 충진제, 마스크, 연고제 또는 필터충진제일 수 있다.The quasi-drug composition of the present invention is not limited thereto, but preferably may be a disinfectant cleaner, shower foam, mouthwash (Gagreen), wet tissue, detergent soap, hand wash, humidifier filler, mask, ointment, or filter filler.
본 발명에 따른 하파고사이드를 포함하는 조성물을 사용할 경우, 상처 치료 효능이 뛰어나므로, 상처 치료를 위한 피부 외용제를 비롯한 의약품 등에 적용되어 사용될 수 있을 것이다.When the composition containing harpagoside according to the present invention is used, it has excellent wound healing efficacy, so it can be applied to pharmaceuticals, including external skin preparations for wound treatment.
도 1은 각 처리군의 상처를 사진으로 확인한 데이터이다.
도 2는 각 처리군의 상처 크기를 그래프로 나타낸 데이터이다.Figure 1 shows data confirming the wounds of each treatment group through photographs.
Figure 2 is data graphically showing the wound size of each treatment group.
이하 하나 이상의 구체예를 실시예를 통해 보다 상세하게 설명한다. 그러나, 이들 실시예는 하나 이상의 구체예를 예시적으로 설명하기 위한 것으로 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다. Hereinafter, one or more embodiments will be described in more detail through examples. However, these examples are intended to illustrate one or more embodiments and the scope of the present invention is not limited to these examples.
실시예 1. 스테로이드 및 하파고사이드 준비Example 1. Preparation of steroids and harpagoside
상처에 스테로이드를 처리하기 위하여, 아세톤에 덱사메타손(Dexamethasone, (DEX), Sigma Aldrich, Korea)을 0.1% 로 희석하여 준비하였다. 농도에 따른 상처 치료 정도를 확인하기 위하여, 바세린 50μg에 하파고사이드(Harpagoside, Chemfaces)를 0.01% 또는 0.1%로 희석하여 준비하였다. To treat the wound with steroids, dexamethasone (DEX, Sigma Aldrich, Korea) was diluted to 0.1% in acetone. To check the degree of wound healing according to concentration, Harpagoside (Chemfaces) was prepared by diluting 50 μg of vaseline to 0.01% or 0.1%.
실시예 2. 상처 치료 확인 Example 2. Confirmation of wound healing
모든 동물 실험은 동국대학교 실험동물운영위원회 승인 프로토콜(승인번호 IACUC-2017-015) 하에 실험을 수행하였으며, 실험동물은 5주령 수컷 BALB/c 마우스(코아텍, 서울)를 사용하였다. 마우스는 6 마리씩 4 그룹(대조군, 스테로이드 처리군, 스테로이드 및 하파고사이드 0.01% 처리군, 스테로이드 및 하파고사이드 0.1% 처리군)으로 무작위로 나누어 실험 하였다. All animal experiments were conducted under protocols approved by the Dongguk University Laboratory Animal Management Committee (approval number IACUC-2017-015), and 5-week-old male BALB/c mice (Coaretech, Seoul) were used as experimental animals. Mice were randomly divided into 4 groups of 6 each (control group, steroid treatment group, steroid and harpagoside 0.01% treatment group, and steroid and harpagoside 0.1% treatment group) for the experiment.
상처 재생 실험을 위하여, 각 그룹의 마우스 등을 면도한 후 직경 5mm 생검펀치(Kai Group, Seki, Japan)로 피부 결손을 만들었다. 실시예 1에서 준비한 덱사메타손을 대조군을 제외한 모든 그룹의 상처에 같은 양으로 14일간 매일 도포하였다. 또한, 스테로이드 및 하파고사이드 0.1% 또는 0.01% 처리군에는 희석한 하파고사이드를 각 상처에 같은 양으로 14일간 매일 도포하였다. 상처의 크기는 피부를 결손 시킨 후 당일, 7일째, 14일째에 측정하여 평균으로 계산하였다. For the wound regeneration experiment, the backs of mice in each group were shaved and skin defects were created with a 5 mm diameter biopsy punch (Kai Group, Seki, Japan). The same amount of dexamethasone prepared in Example 1 was applied to the wounds of all groups except the control group every day for 14 days. Additionally, in the steroid and harpagoside 0.1% or 0.01% treatment groups, the same amount of diluted harpagoside was applied to each wound every day for 14 days. The size of the wound was measured on the first day, 7th day, and 14th day after skin loss and calculated as the average.
그 결과, 도 1 및 도 2에서 보이는 바와 같이, 대조군의 상처의 크기는 7일차부터 눈에 띄게 작아져 14일차에는 약 1.5 mm 정도로 현저히 작아지는 것을 확인하였다. 반면, 스테로이드를 처리한 군들은 7일차까지는 큰 변화가 나타나지 않았으나, 14일차에는 하파고사이드를 처리한 군의 상처가 스테로이드만 처리한 군의 상처 대비 현저히 작아지는 것을 확인하였다. As a result, as shown in Figures 1 and 2, the size of the wound in the control group was confirmed to be noticeably smaller from the 7th day, and to about 1.5 mm on the 14th day. On the other hand, the groups treated with steroids did not show any significant changes until the 7th day, but on the 14th day, it was confirmed that the wounds of the group treated with harpagoside were significantly smaller than those of the group treated only with steroids.
Claims (5)
상기 상처는 스테로이드제로 인하여 상처치유가 지연된 상처인 것인,
상처 치료용 약학적 조성물.
A pharmaceutical composition for treating wounds containing Harpagoside;
The wound is a wound whose healing has been delayed due to steroids,
Pharmaceutical composition for wound treatment.
상기 스테로이드제는 부신피질호르몬제, 남성호르몬제, 여성호르몬제인,
상처 치료용 약학적 조성물.
According to clause 1,
The steroid drugs include corticosteroids, male hormones, female hormones,
Pharmaceutical composition for wound treatment.
상기 조성물은 액제, 연고제, 크림제, 로션제, 스프레이제, 패취제, 겔제 또는 에어로졸제인 것을 특징으로 하는,
상처 치료용 약학적 조성물.
According to clause 1,
The composition is characterized in that it is a liquid, ointment, cream, lotion, spray, patch, gel, or aerosol.
Pharmaceutical composition for wound treatment.
상기 상처는 스테로이드제로 인하여 상처 치유가 지연된 상처인 것인,
상처 치료용 의약외품 조성물.As a quasi-drug composition for promoting wound healing containing Harpagoside;
The wound is a wound whose healing has been delayed due to steroids,
Quasi-drug composition for wound treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210034530A KR102646996B1 (en) | 2021-03-17 | 2021-03-17 | Composition Comprising Harpagoside for Wound Healing |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210034530A KR102646996B1 (en) | 2021-03-17 | 2021-03-17 | Composition Comprising Harpagoside for Wound Healing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20220129790A KR20220129790A (en) | 2022-09-26 |
| KR102646996B1 true KR102646996B1 (en) | 2024-03-13 |
Family
ID=83452359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210034530A KR102646996B1 (en) | 2021-03-17 | 2021-03-17 | Composition Comprising Harpagoside for Wound Healing |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102646996B1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2845624B1 (en) * | 2013-09-10 | 2017-06-07 | Aboca S.p.A. Societa' Agricola | Mucoadhesive devil's claw extracts (harpagophytum procumbens) and uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102222919B1 (en) | 2018-07-06 | 2021-03-04 | 주식회사 씨케이바이오텍 | composition for preventing or treating of wound comprising Indirubin derivative compound |
-
2021
- 2021-03-17 KR KR1020210034530A patent/KR102646996B1/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2845624B1 (en) * | 2013-09-10 | 2017-06-07 | Aboca S.p.A. Societa' Agricola | Mucoadhesive devil's claw extracts (harpagophytum procumbens) and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220129790A (en) | 2022-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10278928B2 (en) | Film-forming pharmaceutical composition for wound healing and method for preparing the same | |
| US8546362B2 (en) | Medicinal cream made using neomycin sulphate, betamethasone valerate, and chitosan, and a process to make the same | |
| KR102568036B1 (en) | Use of oxygenated cholesterol sulfate (OCS) to treat inflammatory skin diseases and skin lesions | |
| US20120022019A1 (en) | Medicinal Steroids Cream And A Process To Make It | |
| WO2008037262A1 (en) | Wound healing composition comprising phosphate, iron and copper | |
| US20110301118A1 (en) | Methods of treatment utilising glucan formulations | |
| CN113274342B (en) | Colchicine external composition | |
| CN103458914B (en) | Skin wound healing compoistion and method of use | |
| KR101642537B1 (en) | A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a process to make it | |
| US20120035144A1 (en) | Medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid, and an antifungal agent, and a process to make it. | |
| KR102646996B1 (en) | Composition Comprising Harpagoside for Wound Healing | |
| WO2020216283A1 (en) | Use of nocardia rubra cell wall skeleton in treatment of thermal injury | |
| KR102638405B1 (en) | Composition Comprising Cimifugin for Wound Healing | |
| EP0365613B1 (en) | Combination of tobramycin and steroids for topical ophthalmic use | |
| KR102669861B1 (en) | Composition Comprising Puerarin for Wound Healing | |
| US20170071973A1 (en) | Extended shelf life wound healing formulation | |
| US20170119792A1 (en) | Methods and compositions for dermatological use comprising clobetasol and halobetasol and biopolymers | |
| US20170119791A1 (en) | Methods and compositions for dermatological use comprsing betamethasone and biopolymers | |
| US20150374644A1 (en) | Therapeutic Composition for the Treatment of Perianal Disorders | |
| US20120101056A1 (en) | Medicinal Cream Made Using Framycetin Sulphate and Chitosan and a Process to Make the Same | |
| WO2016198997A1 (en) | A medicinal cream made using betamethasone valerate and incorporating bio-polymer and a process to make the same | |
| US20170080013A1 (en) | Methods and compositions for dermatological use comprsing hydrocortisone acetate and biopolymers | |
| WO2010122492A1 (en) | A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a corticosteroid, and a process to make it | |
| WO2008022484A2 (en) | Combinations of 5-ht3 receptor antagonists for topical treatment of disorders of skin | |
| WO2010122477A1 (en) | A medicinal antifungal, antibacterial and steroid cream incorporating a biopolymer and a process to make it |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right |